Related Experiment Video

Updated: Aug 11, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis

Tasanee Panichakul1, Pakamas Intachote, Adisak Wongkajorsilp

  • 1Laboratory of Immunology, Chulabhom Research Institute, Bangkok, Thailand. tasanee_p@yahoo.com

Anticancer Research
|February 16, 2006
PubMed
Abstract

Insights

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows variable efficacy against cholangiocarcinoma (CCA). Combining TRAIL with triptolide overcomes TRAIL resistance in CCA cells, offering a new treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells.
  • Cholangiocarcinoma (CCA) cell lines exhibit varying resistance to TRAIL-induced apoptosis.
  • Triptolide, derived from Tripterygium wilfordii, is investigated for synergistic effects.

Purpose of the Study:

  • To investigate the relative resistance of human CCA cell lines to TRAIL.
  • To evaluate the synergistic effect of triptolide in combination with TRAIL against TRAIL-resistant CCA cells.

Main Methods:

  • Six human CCA cell lines were treated with TRAIL and triptolide.
  • Cytotoxicity, apoptosis induction, and expression of anti-apoptotic factors (Mcl-1, cFLIP) were analyzed.
  • Caspase-8 activation was assessed to understand signaling pathways.

Main Results:

  • TRAIL reduced cell viability in 4 out of 6 CCA cell lines in a dose-dependent manner.
  • Combined TRAIL and triptolide treatment enhanced cytotoxicity and apoptosis in resistant CCA cell lines.
  • The combination therapy increased caspase-8 activation more than single-agent treatments.

Conclusions:

  • Human CCA cells display heterogeneous responses to TRAIL-induced apoptosis.
  • Combining TRAIL with triptolide can sensitize TRAIL-resistant CCA cells to apoptosis.
  • This combination therapy presents a potential treatment approach for TRAIL-resistant cholangiocarcinoma.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...